within Pharmacolibrary.Drugs.ATC.J;

model J01EB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.97,
    Cl             = 2.45e-05,
    adminDuration  = 600,
    adminMass      = 1000 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00023999999999999998,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006833333333333333,
    Tlag           = 10.200000000000001
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J01EB05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Sulfafurazole (also known as sulfisoxazole) is a sulfonamide antibacterial drug that inhibits bacterial folic acid synthesis. It has been used primarily to treat urinary tract infections and other susceptible bacterial infections. Its clinical use has declined in many countries due to the availability of safer or more effective agents, and it is not widely used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Ronfeld, RA, &amp; Benet, LZ (1977). Interpretation of plasma concentration-time curves after oral dosing. <i>Journal of pharmaceutical sciences</i> 66(2) 178–180. DOI:<a href=\"https://doi.org/10.1002/jps.2600660211\">10.1002/jps.2600660211</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/839412/\">https://pubmed.ncbi.nlm.nih.gov/839412</a></p></li><li><p>Dean, M, et al., &amp; Levy, G (1980). Serum protein binding of drugs during and after pregnancy in humans. <i>Clinical pharmacology and therapeutics</i> 28(2) 253–261. DOI:<a href=\"https://doi.org/10.1038/clpt.1980.158\">10.1038/clpt.1980.158</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/7398192/\">https://pubmed.ncbi.nlm.nih.gov/7398192</a></p></li><li><p>Kim, E, &amp; Kang, W (2016). Simultaneous determination of N(1)-acetyl sulfisoxazole and its metabolites, and relative bioavailability compare to sulfisoxazole in rats. <i>Journal of pharmaceutical and biomedical analysis</i> 129 117–120. DOI:<a href=\"https://doi.org/10.1016/j.jpba.2016.06.055\">10.1016/j.jpba.2016.06.055</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27423008/\">https://pubmed.ncbi.nlm.nih.gov/27423008</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J01EB05;
